Zanubrutinib
Treatment for Chronic Lymphoid Leukemia
Typical Dosage: 160mg twice daily or 320mg once daily orally
Effectiveness
90%
Safety Score
48%
Clinical Trials
42
Participants
4.5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
48
DangerousModerateSafe
Treatment Details
Dosage Range
160mg twice daily or 320mg once daily orally
Time to Effect
1-3 months
Treatment Duration
Until progression or unacceptable toxicity
Evidence Quality
HIGHConfidence Score
93%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$160,000
Monitoring:$5,000
Side Effect Mgmt:$4,000
Total Annual:$169,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$60,490/QALY
QALYs Gained
1.4
Outcome-Based Costs
Cost per Responder
$187,778
Cost per Remission
$845,000
Comparison vs Acalabrutinib
Cost Difference
$0/year
Same cost
QALY Difference
+0.10 QALYs
Better outcomes
Dominance
DOMINATESBetter + cheaper
Zanubrutinib Outcomes
for Chronic Lymphoid Leukemia
Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+90%
Remission Rate
+20%
Common Side Effects
Neutropenia
+28%
Upper Respiratory Tract Infection
+20%
Bruising
+17%
Diarrhea
+16%
Muscle pain
+15%
Active Clinical Trials
17 active trials recruiting for Zanubrutinib in Chronic Lymphoid Leukemia
Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT06544785RECRUITINGPHASE2
106 participants
INTERVENTIONAL
Barcelona, Spain
Started: Sep 2, 2024
Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL
NCT04515238ACTIVE NOT RECRUITINGPHASE2
42 participants
INTERVENTIONAL
Augsburg, Germany +10 more
Started: Oct 1, 2020
A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia
NCT06637501ACTIVE NOT RECRUITINGPHASE2
94 participants
INTERVENTIONAL
Miami, United States +35 more
Started: Nov 14, 2024
Phase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center Study
NCT07003464NOT YET RECRUITINGPHASE2
30 participants
INTERVENTIONAL
Changchun, China
Started: Jun 15, 2025
MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL
NCT06367374NOT YET RECRUITINGPHASE2
66 participants
INTERVENTIONAL
Started: May 30, 2024
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
NCT06697184ACTIVE NOT RECRUITINGPHASE1, PHASE2
56 participants
INTERVENTIONAL
Tampa, United States +16 more
Started: Jan 23, 2025
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
NCT07277231NOT YET RECRUITINGPHASE3
500 participants
INTERVENTIONAL
Started: Jan 31, 2026
Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT04458610ACTIVE NOT RECRUITINGPHASE2
60 participants
INTERVENTIONAL
Houston, United States
Started: May 26, 2020
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
NCT03824483RECRUITINGPHASE2
230 participants
INTERVENTIONAL
Evanston, United States +7 more
Started: Feb 22, 2019
Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab
NCT05650723RECRUITINGPHASE2
50 participants
INTERVENTIONAL
New York, United States
Started: May 8, 2023
Zanubrutinib, Obinutuzumab, and Sonrotoclax in Previously Untreated Patients With CLL or SLL
NCT06849713RECRUITINGPHASE2
40 participants
INTERVENTIONAL
Boston, United States +1 more
Started: May 16, 2025
Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
NCT06547944ACTIVE NOT RECRUITINGPHASE1
30 participants
INTERVENTIONAL
Tianjin, China
Started: Jan 1, 2024
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
NCT07271667NOT YET RECRUITINGPHASE2
108 participants
INTERVENTIONAL
Started: Dec 1, 2025
Zanubrutinib and Venetoclax in CLL (ZANU-VEN)
NCT05168930RECRUITINGPHASE2
45 participants
INTERVENTIONAL
Scarborough, United States +3 more
Started: Feb 18, 2022
A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT06520098RECRUITINGPHASE2
100 participants
INTERVENTIONAL
San Francisco, United States +3 more
Started: Oct 1, 2025
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
NCT06651970RECRUITINGPHASE4
60 participants
INTERVENTIONAL
Charlotte, United States +22 more
Started: Feb 4, 2025
A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL
NCT03336333ACTIVE NOT RECRUITINGPHASE3
590 participants
INTERVENTIONAL
Augusta, United States +157 more
Started: Oct 31, 2017
Completed Clinical Trials
2 completed trials for Zanubrutinib in Chronic Lymphoid Leukemia
A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia
NCT03734016COMPLETEDPHASE3
652 participants
INTERVENTIONAL
Little Rock, United States +114 more
Started: Nov 1, 2018
Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT03206918COMPLETEDPHASE2
91 participants
INTERVENTIONAL
Beijing, China +10 more
Started: Mar 9, 2017
Showing 20 of 45 total trials